All lobbying filings

SPLITOAK STRATEGIES LLC

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Jan 20, 2026

Official filing document

Bills named in this filing 3

HR 1672
Maintaining Investments in New Innovation Act
HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act

Lobbying activity 1

Medicare/Medicaid

RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; H.R. 946/S. 1862, ORPHAN Cures Act; P.L. 119-21; U.S. Competitiveness

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.